Table 1 Characteristics of patients undergoing desensitization protocols
From: Follow our path with asparaginase activity: one technique, but different uses in clinical practice
Patient | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
Gender | Male | Male | Female | Female |
Age (years | 9 | 5 | 11 | 13 |
Diagnosis | B-ALL | B-ALL | T-ALL | T-ALL |
Treatment protocol | UK ALL R3 | IC-BFM 2009 | IC-BFM 2009 | IC-BFM 2009 |
Previous allergy | Yes | Yes | Yes | Yes |
CTCAE grade | 4 | 2 | 2 | 2 |
Desensitization protocol | Premedication: cetirizine, famotidine, montelukast, and methylprednisolone. Bags of saline with progressively increasing doses and infusion rates | PEG 2500 UI/m2 diluted in 1000 mL of saline. Premedication: hydrocortisone, promethazine, montelukast, and cetirizine | Premedication: promethazine and hydrocortisone | H2 and H1 blockers and corticosteroid pretreatment. 3 bags of saline with different dilution rates: 1:1, 1:10, 1:100 |
Symptoms during desensitization | No | Yes | No | No |
D7 activity levels (IU/mL) | 0.43 | 0.08 | 0.72 | 0.91 |
D14 aActivity levels (IU/mL | NA | 0.03 | 0.64 | 0.34 |
Symptoms improved | Yes | Yes | Yes | Yes |